Macrogenics Inc Stock Price, News & Analysis

MacroGenics (MGNX) has published a manuscript in Molecular Cancer Therapeutics, detailing the preclinical development of MGC018, an antibody-drug conjugate targeting B7-H3 for solid tumors. The ADC shows promising antitumor activity and a favorable safety profile in preclinical models of various cancers. A Phase 1 dose expansion trial for MGC018 is currently recruiting patients with metastatic castration-resistant prostate cancer, triple-negative breast cancer, and non-small cell lung cancer. The company aims to provide updates on the study next year.

MacroGenics, Inc. (NASDAQ: MGNX) announced the publication of interim results from a Phase 1/2 trial of flotetuzumab, aimed at treating acute myeloid leukemia (AML). The trial enrolled 88 patients, revealing a 16.7% complete remission rate in those with primary induction failure or early relapse. Flotetuzumab, a bispecific DART molecule, effectively targets CD123 on leukemic cells and CD3 on T cells, leading to significant T-cell mediated responses. The company plans to expand its trial to 200 patients, with interim results expected later this year, highlighting potential for a pivotal study in this high-unmet-need population.

MacroGenics (Nasdaq: MGNX) announced a $15 million milestone payment triggered by the initiation of a Phase 3 clinical trial for retifanlimab in collaboration with Incyte. This trial evaluates safety and efficacy in treating metastatic non-small cell lung cancer (NSCLC). With this agreement, MacroGenics could receive up to $390 million in development milestones and $330 million in commercial milestones, along with tiered royalties of 15-24% on future sales. The partnership aims to advance retifanlimab across multiple cancer types.

MacroGenics (MGNX) announced promising clinical data from the Phase 1 trial of MGD019, a bispecific PD-1 × CTLA-4 DART molecule targeting advanced solid tumors. The trial showed that MGD019 was well-tolerated, with no dose-limiting toxicities reported. Of the 18 evaluable patients at doses ≥ 3.0 mg/kg, 4 objective responses were noted, including a complete response in metastatic castration-resistant prostate cancer. The company plans to expand the study in patients with microsatellite stable colorectal cancer and non-small cell lung cancer at a recommended Phase 2 dose of 6.0 mg/kg.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced participation in two investor conferences in August 2020. The BTIG Virtual Biotechnology Conference will feature one-on-one meetings and a fire-side chat on August 10 at 12:30 p.m. ET. The Wedbush PacGrow Healthcare Conference is set for August 12 at 8:35 a.m. ET, with similar one-on-one meetings and a corporate overview. Webcasts of both events will be available on the company's website for 30 days post-conference.

MacroGenics, Inc. (NASDAQ: MGNX) announced its financial results for Q2 2020, revealing a net loss of $46.9 million, compared to $31.8 million a year prior. Revenue reached $20.3 million, driven by a $12.0 million agreement with Boehringer Ingelheim. R&D expenses rose to $57.4 million, reflecting increased clinical trial costs. As of June 30, 2020, cash and marketable securities total $232.8 million, extending the company's cash runway into 2023. The company anticipates presenting additional clinical data for its investigational products in upcoming months.

MacroGenics, Inc. (Nasdaq: MGNX) announced it will release its financial results for Q2 2020 after market hours on July 30, 2020. A conference call to discuss these results and recent corporate developments is scheduled for the same day at 4:30 p.m. ET. Interested participants can join by calling (877) 303-6253 (domestic) or (973) 409-9610 (international) using Conference ID 3236629. The call will be available for replay on the company's website for 30 days.

MacroGenics, Inc. (NASDAQ: MGNX) announced positive results from a Phase 2 study published in Lancet Oncology, showcasing the efficacy of margetuximab combined with pembrolizumab as a chemotherapy-free treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). The study found an objective response rate (ORR) of 18% and a disease control rate (DCR) of 53% among treated patients. Notably, the ORR was 44% in patients with high HER2 and PD-L1 expression. The ongoing Phase 2/3 MAHOGANY trial aims to further evaluate this regimen as a first-line therapy.

MacroGenics, Inc. (NASDAQ: MGNX) has announced the hiring of Stephen Eck, M.D., Ph.D., as Senior Vice President, Clinical Development & Chief Medical Officer, effective July 1, 2020. Dr. Eck brings over 20 years of experience in oncology therapeutics from previous roles at Immatics US and Astellas Pharma, among others. This addition is expected to enhance MacroGenics' presence in clinical development. Ezio Bonvini, M.D., will resume his role as Chief Scientific Officer after overseeing clinical development on an interim basis.